Business
Ninth Published Human Trial on Niagen® Nicotinamide Riboside (NR) Shows Increase in NAD+ Levels, Additional Research Highlights Downfalls of Nicotinamide Mononucleotide (NMN)
ChromaDex highlights additional clinical and preclinical research strengthening science and understanding behind Niagen® (patented nicotinamide riboside) LOS
About this update from Niagen Bioscience, Inc.
[{"type":"text","content":"\nChromaDex highlights additional clinical and preclinical research strengthening science and understanding behind Niagen® (patented nicotinamide riboside)\n\n LOS ANGELES--(BUSINESS WIRE)--\nChromaDex Corp. (NASDAQ:CDXC) today announced the results of several new studies, which have uncovered new clinical and preclinical findings for its Niagen® (nicotinamide riboside, or NR) cellular nutrient, paving the way for continued research. Through its industry leading research program, called the ChromaDex External Research Program (CERP), ChromaDex provides its patented nicotinamide riboside (NR, or Niagen) ingredient to research institutions and universities at no cost. ChromaDex continues to support NAD+ research and through CERP has developed a global community of esteemed researchers exploring the potential Niagen and NAD+ can have on human health.\n\n\nNewly published clinical research in the American Journal of Clinical Nutrition examined nicotinamide riboside supplementation at 1 gram per day for six weeks in healthy overweight or obese men. NR modestly improved body composition and acetyl carnitine (a fatty acid transporter) concentrations in skeletal muscle and increased metabolic rate during sleep.\n\n\nPreclinical research from Dr. Charles Brenner and researchers at three U.S. universities demonstrated SARS-CoV-2 (COVID-19)-induced NAD+ dysregulation in an in vitro model, as well as the lung tissue from infected animals and a deceased COVID-19 patient. This is the first of several studies examining the potential role of NAD+ in the innate immune response to SARS-CoV-2 in the midst of this pandemic.\n\n\nA preclinical study published in Nature Communications investigating neurological diseases (such as Alzheimer’s and Parkinson’s) in mouse models found that NR significantly increased brain NAD+ levels, partially blocked neurodegeneration and increased the lifespan of neurodegenerative mice by 30%. Importantly, the study also found that NMN (nicotinamide mononucleotide) was not at all effective at raising NAD+ levels in the neurodegenerative mouse model brain.\n\n\nA review on the regulation of cellular aging from Biomolecules specifically recognized Niagen® as a unique NAD+-boosting agent with regulatory acceptance.\n\n\nA study and review from Nature Metabolism highlighted the potential of a relative of NR called dihydroni...